Article

Classical swine fever: comparison of oronasal immunisation with CP7E2alf marker and C-strain vaccines in domestic pigs.

Veterinary and Agrochemical Research Centre (VAR), Department of Virology, Groeselenberg 99, B-1180 Brussels, Belgium.
Veterinary Microbiology (Impact Factor: 3.13). 09/2009; 142(1-2):59-68. DOI:10.1016/j.vetmic.2009.09.044
Source: PubMed

ABSTRACT Effective oronasal vaccination against classical swine fever (CSF) is essential to achieve protection in wild boar. However the currently available live CSF vaccines, e.g. C-strain, do not allow serological differentiation between infected and vaccinated animals (DIVA). A modified live marker vaccine candidate (CP7E2alf) has been recently developed (Reimann et al., 2004). This communication reports the comparison of CP7E2alf and C-strain virus vaccines during 98 days following oronasal immunisation in domestic pigs. C-strain vaccine virus was consistently detected in tonsils of all (n=30) animals from 3 to 77 days post vaccination (dpv) and in blood (n=36) between 3 and 13dpv by CSFV-specific rRT-PCR. CP7E2alf virus RNA was detected in 6 animals slaughtered between 4 and 63dpv by a BVDV-specific rRT-PCR. The chimeric virus was not detected in blood samples. As detected by CSFV E2-specific antibody ELISA and virus neutralisation tests, seroconversion first occurred at 11dpv in the C-strain vaccinated group and between 11 and 15dpv in the CP7E2alf vaccinated group. The serological response was still present at 98dpv. The CP7E2alf serological response remained negative using the CSFV E(rns) ELISA whereas seroconversion occurred in the C-strain vaccinated group. In conclusion, the primary replication site of CP7E2alf vaccine virus was found to be the tonsils as in the C-strain and virulent field strains. Persistence of CP7E2alf in the tonsils was also demonstrated up to 63dpv. Both vaccines showed immunogenicity after oronasal administration in domestic pigs. In contrast to the C-strain, CP7E2alf vaccine allowed the use of DIVA approaches in serological tests. This study confirms CP7E2alf as a promising marker vaccine candidate for oronasal vaccination programmes to control CSF in domestic pigs and wild boar.

0 0
 · 
0 Bookmarks
 · 
82 Views
  • [show abstract] [hide abstract]
    ABSTRACT: Posterior dislocation of IOLs has been reported following Nd:YAG laser for anterior capsule contraction in only 3 cases and these involved plate haptic silicone lenses; while the dislocation of IOLs into the vitreous cavity following posterior Nd:YAG laser capsulotomy have been reported in plate haptic silicone lenses and single piece hydrophilic acrylic (polymacon) lenses. We report a patient who suffered the delayed dislocation of an injectable hydrophilic acylic IOL (SlimFlex-m 123 IOL, PhysIOL, Liège, Belgium) following combined Nd:YAG laser anterior and posterior capsulotomy. We also explore the factors that may predispose to anterior capsular contraction syndrome and IOL dislocation.
    Contact lens & anterior eye: the journal of the British Contact Lens Association 04/2011; 34(4):193-5.
  • [show abstract] [hide abstract]
    ABSTRACT: Chahbahar area is located at the southern coasts of Iran in the Omman Sea. This paper examines possible examples of offshore wave power installations at Chahbahar area in the Omman Sea. The study aims at showing the physical possibilities of wave energy and electric power generation based upon point-absorbers and attenuator devices in the selected site. This site has been chosen to represent a range of offshore wave climates around Chahbahar area. Hindcasting data is used allowing estimations of wave energy generated and results show promising conditions in this area. Wave climate power density, or incident wave power per meter of WEC device reach a maximum value 24kW/m with monthly maximum of 9.70kW/m and annual average equals to 4.14kW/m. We study power recoverable possibility for three different wave energy devices, based on their published power matrices; 750kW Pelamis device, hypothetical modified 1500kW Pelamis device and hypothetical 750kW Single Point Absorber (SPA). Results show corresponding annual electric energy generation for this devices are 0.32GWh, 4.9GWh and 2GWh respectively. Finally, we determine appropriate WEC device for selected site. Also, we propose a solution for some environmental problem.
    Renewable & Sustainable Energy Reviews - RENEW SUSTAIN ENERGY REV. 01/2011;
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: The conventional C-strain vaccine induces early protection against classical swine fever (CSF), but infected animals cannot be distinguished from vaccinated animals. The CP7_E2alf marker vaccine, a pestivirus chimera, could be a suitable substitute for C-strain vaccine to control CSF outbreaks. In this study, single oral applications of CP7_E2alf and C-strain vaccines were compared for their efficacy to induce protection against a CSF virus (CSFV) challenge with the moderately virulent Bas-Rhin isolate, in pigs as early as two days post-immunization. This work emphasizes the powerful potential of CP7_E2alf vaccine administered orally by a rapid onset of partial protection similar to that induced by the C-strain vaccine. Furthermore, our results revealed that both vaccinations attenuated the effects induced by CSFV on production of the pig major acute phase protein (PigMAP), IFN-alpha, IL-12, IL-10, and TGF-beta1 cytokines. By this interference, several cytokines that may play a role in the pathogeny induced by moderately virulent CSFV strains were revealed. New hypotheses concerning the role of each of these cytokines in CSFV pathogeny are discussed. Our results also show that oral vaccination with either vaccine (CP7_E2alf or C-strain) enhanced CSFV--specific IgG2 production, compared to infection alone. Interestingly, despite the similar antibody profiles displayed by both vaccines post-challenge, the production of CSFV-specific IgG1 and neutralizing antibodies without challenge was lower with CP7_E2alf vaccination than with C-strain vaccination, suggesting a slight difference in the balance of adaptive immune responses between these vaccines.
    Veterinary Research 02/2013; 44(1):9. · 3.43 Impact Factor

Full-text (2 Sources)

View
13 Downloads
Available from
Dec 19, 2012